-+ 0.00%
-+ 0.00%
-+ 0.00%

Ensysce Biosciences Q3 net loss widens to $82.11 million

PUBT·11/12/2026 21:34:39
Listen to the news
Ensysce Biosciences Q3 net loss widens to $82.11 million
  • Ensysce Biosciences’ third-quarter 2026 net loss attributable to common stockholders widened to $82.32 million.
  • The loss included a $79.91 million noncash charge for acquired in-process research and development related to the Cy Biopharma acquisition.
  • Quarterly federal grant funding rose to $2.18 million; cash and cash equivalents reached $29.67 million at September 30.
  • UK regulators requested additional information for CY200’s Phase 2a trial application on November 6; the company is preparing its response.
  • Enrollment concluded in the final stage of the PF614-MPAR-102 study in August, evaluating the opioid candidate’s overdose protection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ensysce Biosciences Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611121615ACCESSWRNAPR_____1250779) on November 12, 2026, and is solely responsible for the information contained therein.